Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Cancer cells can survive anti-cancer treatments through cellular senescence.
• Senescent tumor cells promote tumor growth and metastasis.
• Senolytic therapy aims to eliminate these harmful senescent cells.

Purpose of the Study:

• To investigate the survival mechanisms of senescent tumor cells.
• To identify novel therapeutic targets for senolytic therapy.

Main Methods:

• Single-cell RNA-sequencing was used to analyze senescent tumor cells.
• Inhibitors targeting anti-apoptotic genes (Bcl-2 and Mcl-1) were tested in preclinical models.

Main Results:

• Senescent tumor cells depend on the anti-apoptotic gene Mcl-1 for survival.
• Mcl-1 is upregulated in senescent cells, even those with low Bcl-2 expression.
• The Mcl-1 inhibitor S63845 eradicated senescent tumor cells and metastases in mice, outperforming the Bcl-2 inhibitor Navitoclax.

Conclusions:

• Mcl-1 is a critical survival factor for senescent tumor cells.
• Targeting Mcl-1 represents a promising senolytic strategy for cancer treatment.
• This study reveals a key vulnerability in senescent tumor cells exploitable for therapy.